• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Schulman Associates IRB acquires Independent IRB

Schulman Associates IRB acquires Independent IRB

December 5, 2011
CenterWatch Staff

Schulman Associates Institutional Review Board has acquired Independent
Investigational Review Board
. The transaction allows both organizations, which protect the rights of human research subjects, to provide a more comprehensive suite of review services for pharmaceutical, medical device, contract research organization and clinical research site customers.

"The strengths of the two organizations are remarkably complimentary," said Michael Woods, president and CEO of Schulman. "We are very excited by the added resources and capabilities Independent brings to the combined company."

With offices in Cincinnati, Ohio, and Plantation, Fla., the combined organization will provide research review services for a broad range of therapeutic areas and types of human subject research. Separately, each organization is accredited by Association for the Accreditation of Human
Research Protection Programs
(AAHRPP), and each has a clean recent audit
history with FDA.

"Joining with Schulman allows Independent to provide the advantages of enhanced WebPortal and IT features to our established customer base," said Kim Lerner, outgoing CEO of Independent.

Anita McSharry, former president of Independent, added, "This is a perfect example of one plus one equaling far more than two. The benefits extend to every research site, sponsor and CRO that uses our services. The employees
of both companies also benefit from the additional resources that allow them to accomplish their mission to protect the rights of human research subjects more efficiently than ever."

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing